WILEX AG Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (29)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“WILEX AG - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by WILEX AG. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “7” cancer drugs in clinical pipeline and majority of them are in preclinical phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“WILEX AG - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“WILEX AG - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by WILEX AG. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “7” cancer drugs in clinical pipeline and majority of them are in preclinical phase.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“WILEX AG - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. WILEX AG

  1.1 Business Overview

  1.2 WILEX AG Cancer Pipeline Overview

 

2. WILEX AG Cancer Drugs in Research Phase

  2.1 Antibody-Drug Conjugates - Advanced Proteome Therapeutics/ Heidelberg Pharma

 

3. WILEX AG Cancer Drugs in Preclinical Phase

  3.1 Antibody Targeted Amanitin Conjugates - Heidelberg Pharma

  3.2 Antibody Therapeutics - F-star

  3.3 PSMA ATAC Therapeutics - Heidelberg Pharma

  3.4 Antibody-Drug Conjugates – Heidelberg

 

4. WILEX AG Cancer Drugs in Clinical Phase

  4.1 Girentuximab Companion Diagnostic - Wilex/Nuclea Biotechnologies

 

5. WILEX AG Cancer Drugs in Phase-II/III

  5.1 Girentuximab-Zr-89

 

6. Discontinued in Cancer Drugs in Clinical Pipeline

  6.1 Imexon - Heidelberg Pharma

  6.2 Cancer Therapeutics – Heidelberg

  6.3 Anthracyclines - Galilaeus Oy

  6.4 HDP 990007

 

7. Suspended in Cancer Drugs in Clinical Pipeline

  7.1 Girentuximab

  7.2 Fosfluridine Tidoxil

  7.3 Clofarabine - Heidelberg Pharma


Figure 1-1: WILEX AG Cancer Pipeline by Phase (%)

Figure 1-2: WILEX AG Cancer Pipeline by Phase (Number)

Figure 1-3: WILEX AG Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (%)

Figure 1-4: WILEX AG Cancer Drugs Discontinued & Suspended in Clinical Pipeline by Phase (Number)